News Releases
-
Bachem reports excellent results for the first half-year 2021
Sales of CHF 500 million are now expected for the year 2021.Released by: Bachem
-
Bachem and Novo Nordisk Redesign SPPS for Green Chemistry
Replacing gold standard solvents to provide a greener alternative.Released by: Bachem
-
APIs
Propofol – A Bachem Success Story
The COVID-19 pandemic has rapidly expanded awareness of the API Propofol, produced by Bachem in Vionnaz.Released by: Bachem
-
Bachem News & Events
Learn more about what is happening at Bachem, what activities we have coming up, and what events you can meet us both virtually and in-person.Released by: Bachem
-
Microbiology
On-Demand Webinar: Microbial In-Use Studies
In this webinar, Alcami’s Brent Harlow will guide you through the necessity of these studies and how to successfully perform them for FDA approval.Released by: Alcami
-
Analytical Services | Biologics, Proteins, Vaccines | Extractables and Leachables
On-Demand Lab Open House
Sign up to get a close-up look at our US network of laboratories and hear about our expansion plans.Released by: Alcami
-
Formulation Development
Tryp Therapeutics Partners with Alcami for Proprietary Formulations
The agreement represents another step toward the proprietary manufacturing, formulation, and delivery of products for Tryp’s PFNTM program.Released by: Alcami
-
Tablet Development Process Training - July 20-21
This course provides comprehensive insight into the tablet development process to provide powerful tools that you can put to work immediately.Released by: Federal Equipment Company
-
Promotions & Moves
Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer
He succeeds Walter J. Kaczmarek III, who is stepping down as Chief Executive Officer.Released by: Alcami
-
Humanigen & Emergent Biosolutions Announce Agreement for Phase 3 Covid-19 Therapeutic Candidate
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.Released by: Emergent BioSolutions
-
Vetter continues its successful performance at the 2021 CMO Leadership Awards
Winning five core categories reaffirms Vetter as a trusted solution provider, particularly during globally challenging times.Released by: Vetter Pharma International
-
-
Vetter continues to implement its long-term sustainability strategy
Minister of Transport praises the commitment of the pharmaceutical service provider during global turbulent timesReleased by: Vetter Pharma International
-
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
...Released by: Syngene
-
CCRM and McMaster Innovation Park (MIP) Partner to Build and Operate Biomanufacturing Campus
...Released by: CCRM
-
-
Syngene International Q2 profit up 64 pc to Rs 128 cr
Press Trust of India | New DelhiReleased by: Syngene
-
Vetter continues its long-term investment strategy to sustain future growth
Existing buildings are repurposed as others continue to be built and recently housedReleased by: Vetter Pharma International
-
Syngene joins global consortium to accelerate research in COVID-19 testing
The consortium brings together a diverse group of companies with synergistic areas of expertiseReleased by: Syngene
-
